A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
2025-01-05
عنوان الدراسة
A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
داعم الدراسة
Global Therapeutics Inc
دواء الدراسة
Osivelotor
رقم بروتوكول الدراسة
C5351004 (GBT021601)
حالة الدراسة
Ongoing
موقع الدراسة
Prince Mohammad Bin Naser Hospital (Jazan), King Abdulaziz Medical City NG (Riyadh)
مرحلة الدراسة
2/3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。